肿瘤细胞治疗研究
FRONTIER PAPERS
Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity.
同时靶向 PD-L1 与 ErbB2 可通过对抗原异质性提供抵抗力并经协同激活放大抗肿瘤信号，增强 CAR-NK 细胞对难治性实体瘤的疗效。
Breaking the barrier: Synergistic 2B4.4-1BB signaling potentiates HER2-CAR NK cells to penetrate and destroy ADCC-resistant tumors.
Injectable Hydrogels for Breast Cancer Therapy: From Tumor Microenvironment-Responsive and Actively Targeted Drug Delivery to Immunotherapy and Theran
乳腺癌治疗仍面临诸多挑战，包括局部复发、全身毒性、肿瘤异质性、耐药和免疫抑制。
Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy.
我们的研究结果表明，抑制IL-10分泌可增强CAR工程化NK-92细胞的治疗潜力，提示这一策略有望成为临床转化的有前景途径。
ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.
嵌合抗原受体工程化 NK 细胞在过继性肿瘤免疫治疗中展现出前景。
Chimeric antigen receptor NK cells for breast cancer immunotherapy.
乳腺癌是全球女性中最常见的恶性肿瘤，需要超越手术、化疗、放疗和内分泌治疗等传统疗法的创新治疗策略。
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.
HER2 扩增见于约 5% 的结直肠癌（CRC）病例，且仅部分与联合人表皮生长因子受体 2（HER2）/表皮生长因子受体（EGFR）靶向治疗的临床应答相关。
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
乳腺癌细胞上ICAM-1的下调是逃逸trastuzumab触发的ADCC的关键机制。相反，CAR-NK细胞能够克服由ICAM-1减少引起的癌细胞耐药，凸显了CAR-NK细胞在肿瘤免疫治疗中的潜力。
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.
颅内注射HER2靶向CAR-NK细胞在复发性GB患者中是可行且安全的。1 108个NK-92/5.28.z细胞被确定为后续扩展队列重复局部注射CAR-NK细胞的最大可行剂量。
Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy.
HER2 阳性乳腺癌脑转移（HER2 + BCBM）是一种复发率高、预后差的难治性恶性肿瘤。
MEMBER ACCOUNT
登录成功会直接打开下一页。
